CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Tryp Therapeutics Breaks New Grounds...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Tryp Therapeutics Breaks New Grounds...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

Nabriva Therapeutics and Vizient Join Hands to Offer XENLETA

Life Sciences Review Life Sciences Review | Tuesday, September 21, 2021
Tweet

Nabriva Therapeutics plc and Vizient together have agreed to offer XENLETA to treat community-acquired bacterial pneumonia (CABP).


FREMONT, CA: Nabriva Therapeutics plc and Vizient join hands to offer XENLETA, a treatment for community-acquired bacterial pneumonia (CABP), as a contracted product through Vizient's Pharmacy Network Program. To enhance patient outcomes and minimize costs, Vizient offers knowledge, analytics, and advisory services, as well as a contract portfolio totaling more than $110 billion in annual purchasing volume.


Nabriva CEO Ted Schroeder commented, “We are excited by Vizients decision to enter into an agreement to make XENLETA available to their Hospital Pharmacy Network, enabling access across Vizient member hospitals, which make up more than half of U.S. hospitals. Based on data from the Healthcare Cost and Utilization Project, it is estimated approximately 3 million adults are diagnosed with CABP in the hospital setting annually. Importantly, many of these patients may be at increased risk for adverse effects associated with respiratory fluoroquinolone or reside in areas with a high (>25%) prevalence of macrolide resistance. 


We are enthusiastic about the opportunity to provide clinicians a short-course, IV and oral monotherapy treatment option that addresses these unmet medical needs for their CABP patients.”


Nabriva Therapeutics is a biopharmaceutical business focused on researching and marketing novel anti-infective drugs for the treatment of serious illnesses. Nabriva Therapeutics was awarded a U.S. patent. XENLETA®, the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia, has received FDA approval (CABP). CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complex urinary tract infections (cUTI), including acute pyelonephritis, is also being developed by Nabriva Therapeutics. Merck & Co. subsidiaries have an exclusive arrangement with Nabriva. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO®.


Weekly Brief

loading
Top 10 Leading BioTech Solution Companies - 2021
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

The Importance of Technology in Multinational Clinical Research

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/nabriva-therapeutics-and-vizient-join-hands-to-offer-xenleta-nwid-569.html